Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 8, 2002, Pages 2564-2568

  Kirkpatrick, William R ^a   Perea, Sofia ^a   Coco, Brent J ^a   Patterson, Thomas F ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; CASPOFUNGIN; CYCLOPHOSPHAMIDE; TRIAMCINOLONE; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CYCLOPEPTIDE; PEPTIDE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GUINEA PIG; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MORTALITY; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SURVIVAL; TREATMENT PLANNING; ANIMAL; DRUG COMBINATION; MICROBIOLOGY; ORGAN CULTURE TECHNIQUE;

AMPHOTERICIN B; ANIMAL; ANTIBIOTICS, ANTIFUNGAL; ANTIBIOTICS, PEPTIDE; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; GUINEA PIGS; MALE; ORGAN CULTURE; PYRIMIDINES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TRIAZOLES; ANIMALS; ANTI-BACTERIAL AGENTS; ORGAN CULTURE TECHNIQUES; PEPTIDES; PEPTIDES, CYCLIC;

EID: 0035991955     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.8.2564-2568.2002     Document Type: Article

References (29)

1. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): Efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
2. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
3. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates
4. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans
5. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species
6. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
7. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: Demonstration of efficacy of caspofungin acetate
8. Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus
9. Invasive aspergillosis
10. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
11. Combination therapy in experimental invasive aspergillosis
12. Future directions of antifungal chemotherapy
13. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191
14. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits
15. Efficacy of voriconazote in a guinea pig model of disseminated invasive aspergillosis
16. Aspergillus fumigatus and aspergillosis
17. Optimizing voriconazole susceptibility testing of Candida: Effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility
18. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs
19. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus. Candida, and Cryptococcus infections
20. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis
21. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis
22. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis
23. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes
24. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes
25. Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis
26. Activity of terbinafine against serious fungal pathogens
27. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species
28. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models